Navigation Links
PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
Date:4/3/2012

ANNAPOLIS, Md., April 3, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) today announced that it has secured $7.5 million in senior secured credit facilities from GE Capital, Healthcare Financial Services consisting of a $2.5 million term loan and a revolving line of credit of up to $5 million.

Linda L. Chang, Senior Vice President and Chief Financial Officer, commented, "We are very pleased to partner with GE Capital – a recognized leader in healthcare financing.  This financing further strengthens our balance sheet and provides us with increased flexibility to manage our working capital requirements."

"Our expected 2012 monthly cash burn is less than $500,000 per month based on currently projected activities on our contracts," Ms. Chang continued. "Given that PharmAthene had $19.2 million in cash and cash equivalents, short term investments, and net receivables as of December 31, 2011, this financing provides an additional liquidity cushion until the time in 2013 when we anticipate receiving final resolution of the litigation with SIGA Technologies."

For a summary of the terms of the credit facility, see the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date hereof.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.  PharmAthene's lead product development programs include:

  • SparVax™ a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim® a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Recombinant BChE a novel bioscavenger for
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
2. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
3. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
4. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
5. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
6. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
7. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
8. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
9. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
10. PharmAthene Completes $6.5 Million Registered Direct Offering
11. PharmAthene Reports First Quarter 2011 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... Nuvilex, Inc. (OTCQB: NVLX) – According to ... are living with diabetes, with  that number expected to ... market for diabetes treatments is approximately $500 billion.  ... from pancreatic cancer.  Pancreatic cancer is the fourth most ... the United States , and according to ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... The Wisconsin Alumni Research Foundation ( WARF ) and ... nutritional supplement manufacturer today with willful and deliberate patent ... , ,The French company, Arkopharma , and its ... the suit when they continued to sell certain products ...
... - The growing body of university research under development beyond ... grow at an even faster pace as the result of ... System presidents and the Wisconsin Alumni Research Foundation. ... for researchers at UW System schools. The focus, however, extends ...
... Lee Dreyfus made a few waves when he suggested ... blue-eyed Arabs of the Upper Midwest" by selling fresh ... many of his ideas, often delivered off-the-cuff to mask ... Dreyfus proposal simultaneously stirred the imagination and set off ...
Cached Biology Technology:WARF sues French company over patent violation 2WiSys to distribute $1 million in research funds 2WiSys to distribute $1 million in research funds 3WiSys to distribute $1 million in research funds 4Fresh water could be a deep economic wellspring for Wisconsin 2Fresh water could be a deep economic wellspring for Wisconsin 3
(Date:10/14/2014)... Ohio (Oct. 14, 2014)—It,s been millions of years since ... a team led by Ohio University scientists is breathing ... model airflow through dinosaur snouts. The research has important ... only breathe but to enhance the sense of smell ... ,nosy, animals," said Ohio University doctoral student Jason Bourke, ...
(Date:10/14/2014)... kind of stem cell that can become either a liver ... to a study published today in the journal Stem ... contradicts current theory on how organs arise from cell layers ... and future treatment for, liver cancer., Thanks to stem cells, ... made up of more than 200 cell types. The original, ...
(Date:10/14/2014)... team of scientists led by researchers at the ... University of Miami Miller School of Medicine (UMMSM) ... pathway underlying bipolar (manic depressive) disorder, a breakthrough ... bipolar affective disorder, as well as depression and ... published online this week in Nature Molecular ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... known PSA blood test for prostate cancer in men may ... breast cancer, the most common form of cancer in women ... ACS journal Analytical Chemistry . Chien Chou and ... test also is a potential biomarker of breast cancer in ...
... is available in German and Spanish . ... Chile pose a higher threat to its neighbour, Argentina, than ... of Concepcin in Chile and the Helmholtz Centre for Environmental ... particular, 22 non-native species which occur in Chile on connecting ...
... has shown that light is the key to getting our ... exploring the resynchronisation mechanism in insects has discovered a molecule ... University of London looked at the impact of light on ... flies. They identified a novel molecule, QUASIMODO (QSM), which was ...
Cached Biology News:Chile is more dangerous for Argentina than vice versa 2Chile is more dangerous for Argentina than vice versa 3Newly discovered molecule essential to resetting 'body clocks' 2
Canine Serum...
NORMAL DONOR DONKEY SERUM...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Biology Products: